Aprotinina en el control de las hemorragias en cirugía

Medicina Clinica

Volumn 106, Issue 8, 1996, Pages 307-316

  Rocha, Eduardo ^a,b   Pâramo, José Antonio ^a   Hermida, José ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Universitaria de Navarra   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ;

ANAPHYLACTIC SHOCK; DRUG MECHANISM; EDEMA; FIBRINOLYSIS; HEART SURGERY; HEMOSTASIS; HUMAN; NEPHROTOXICITY; POSTOPERATIVE HEMORRHAGE; REVIEW;

APROTININ; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; CLINICAL TRIALS; CONTROLLED CLINICAL TRIALS; HEMOSTASIS; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; LIVER TRANSPLANTATION;

EID: 0029914262     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (161)

1. Kunitz M, Northrop JH Isolation from beef pancreas of crystalline trypsino-gen, trypsin, a trypsin inhibitor, and an inhibitor trypsin compound. J Gen Physiol 1936; 19: 991-1.007.
2. Verstrate M. Clinical application of inhibitors of fibrinoiysis Drugs 1985, 29: 236-261
3. Trautschold I, Werle E, Zickgraf-Rüdel G. Trasylol Biochem Pharmacol 1967; 16 59-72
4. Chauvet J, Nouvel G, Acher R. Structure primaire d'un inhibiteur prancréatique de la trypsine (inhibiteur de Kunitz et Northrop) I Enchainements N- et C terminaux. Biochim Biophys Acta 1966; 115: 121-129
5. Kaller H, Patzschke K, Wegner LA. Horster FA Pharmakokinetic observations following intravenous administration of radioactive labelled aprotinin in volunteers Eur J Drug Metabolism Pharma 1978; 3: 79-85.
6. Van Oeveren W, Jansen NJG. Bidstrup M, Royston D. Westaby S, Neuhof H et al. Effects of aprotinin of hemostatic mechanisms during cardiopulmonary bypass Ann Thorac Surg 1987, 44:640-645
7. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hausen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement and renal function after cardiopulmonary bypass J Thorac Cardiovasc Surg 1991; 101 958-967
8. Hunt BJ. Modifying perioperative blood loss. Blood Rev 1991; 5: 168-176.
9. Hunt BJ, Cottam S, Segal H, Ginsburg R, Potter D Inhibition by aprotinin of t-PA mediated fibnnolysis during orthotopic liver transplantation. Lancet 1990; 336 381
10. España F, Estellés A, Griffin JH, Aznar J, Gilabert J Aprotinin is a competitive inhibitor of activated protein C Thromb Res 1989; 56: 751-756.
11. Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE Aprotinin in cardiopulmonary bypass-effects on the Hageman factor (FXII)-Kallhkrein system and blood loss Blood Coagul Fibrinol 1992, 3 99-104
12. Westaby S Aprotinin in perspective Ann Thorac Surg 1993, 55: 1 033-1 041.
13. Pintigny D, Dhachary-Prigent J. Aprotinin can inhibit the proteolytic activity of thrombin. A fluorescence and an enzymatic study Eur J Biochem 1992; 207 89-95.
14. Havel MP, Griesmacher A, Weigel G, Owen A, Simon P, Teufelsbaver H et al Aprotinin increases release of von Willebrand factor in cultured human umbilical vein endothelial cells. Surgery 1992, 112. 573-577.
15. 2, or vWF from cultured human endothelial cells Thromb Haemostas 1992; 67. 172-175
16. Marx G. Pokar H, Reuther H, Doering V Tilsner V The effects of aprotinin on hemostatic function during cardiac surgery. J Cardiothorac Vase Anesth 1991; 5: 467-474
17. Azougasg Oulane F, Toulemonde F, Doutremepuich F, Doutremepuich C Effects of aprotinin on heparin activities and heparin neutralization with protamine Thromb Res 1992; 68:185-193.
18. Freeman JG, Tuner GA, Venables CW, Latner AL Serial use of aprotinin and incidence of allergic reactions Curr Med Res Opin 1983, 8 559-561.
19. Boldt J, Knothe C, Zickmann B. Wege N, Dapper F, Hempelmann G. Comparison of two aprotinin dosage regimens m pediatric patients having cardiac operations J Thorac Cardiovasc Surg 1993; 105:705-711
20. Bachman F, McKenna R, Cole ER, Najati H. The hemostatic mechanism after openheart surgery I Studies on plasma coagulation factors and fibrinolysis in 512 patients after extracorporeal circulation J Thorac Cardiovasc Surg 1975; 70: 76-85
21. Woodman RC, Harker LA Bleeding complications associated with cardiopulmonary bypass Blood 1990, 76: 1 680-1 697
22. Verska JJ, Lonser ER, Brewer LA. Predisposing factors and management of hemorrhage following open heart surgery. Moscú 10th Congress of the International Cardiovascular Society 1971, agosto 26-28.
23. Barrera JM, Bruguera M, Ercilla MG, Sénchez Tapias JM, Costa J, Gelabert A et al. Hepatitis postransfusional después de cirugía cardíaca Incidencia, clinica y pronóstico. Med Clin (Barc) 1987; 89. 759-762.
24. Mammen F, Koets MH, Washington BC, WoIk LW, Brown JM, Burdick M et al. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 1985; 11: 281-292.
25. Dale J, Lilleasen P, Erikssen J. Hemostasis after open-heart surgery with extreme or moderate hemodilution. Eur Surg Res 1987, 19. 339-347.
26. Alpert J. Bhaktan EK, Giechiusky I, Gilbert L, Brener BJ, Brief DK et al Vascular complications of intraortic balloon pumping Arch Surg 1976; 111: 1.190-1 196
27. McKenna R, Bachmann F, Whitaker B. Gilson JR, Weinberg MJ. The hemostatic mechanism after open-heart surgery II. Frequency of abnormal platelet functions during and after extracorporeal circulation J Thorac Cardiovasc Surg 1975; 70: 298-308
28. Milam JD, Austin SF, Martin RF, Keats AS, Cooley DA Alteration of coagulation and selected clinical chemistry parameters in patients undergoing open heart surgery without transfusions. Am J Clin Pathol 1981; 76. 155-162.
29. Mohr R, Golan M. Martinowitz U, Rosner E, Goor DA, Ramot B. Effect of cardiac operation on platelets. J Thorac Cardiovasc Surg 1986; 92: 434-441.
30. Addonizio VP Jr, Fischer CA, Jenkin BK, Strauss JF III, Musial JF, Edjunds LH Jr IIIoprost (ZK36374), a stable analogue of prostacyclin, perserves platelets during stimulated extracorporeal circulation. J Thorac Cardiovasc Surg 1985, 89. 926-933
31. Harker LA, Malpass TW, Branson HE, Hessel E, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass. Acquired transient platelet dysfunction associated with selective α-granule release. Blood 1980; 56: 824-834
32. Malpass TW, Amory DW, Harker LA, lvey TD. Williams DB The effect of prostacyclin infusion on platelet hemostatic function in patients undergoing cardiopulmonary bypass J Thorac Cardiovasc surg 1984; 87: 550-555
33. George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N et al Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects and observations in patients during adult respiratory distress syndrome and cardiac surgery J Clin Invest 1986, 78: 340-348
34. Musial J, Niewiarowski S, Hershock D, Morinelli TA, Colman RW, Edmunds LH. Loss of fibrinogen receptors from the platelet surface during simulated extracorporeal circulation J Lab Clin Med 1985, 105: 514-526
35. Wenger RK, Lukasiewicz H, Mikuta BS, Niewiarowski S, Edmunds LH. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989; 97: 235-239
36. Wildevuur C, Eijsman L, Roozendaal KJ. Harder MP Chang M, Van Oeveren W. Platelet preservation during cardiopulmonary bypass with aprotinin. Eur J Cardiothorac Surg 1989; 3: 533-538
37. Dechavanne M, Efrench M, Pages J, Effrench P, Boukerche H, Bryron PA et al. Significant reduction m the binding of a monoclonal antibody (LYP 18) directed against the IIb/IIIa glycoprotein complex to platelets of patients having undergone extracorporeal circulation Thromb Haernost 1987; 57:106-110.
38. Van Oeveren W, Eijmsman L. Roozendaal KJ, Wildevuur CRH Platelet preservation by aprotinin during cardiopulmonary bypass [carta]. Lancet 1988; 1; 644
39. Adelman B, Michelson A, Loscalzo J. Greeberg J, Handin RI. Plasmin effect on platelet glycoprotein IB-von Willebrand factor interactions. Blood 1985, 65: 32-40
40. Brody Jl, Pickering NJ, Fink GB. Concentrations of factor VIII-related antigen and factor XIII during open heart surgery. Transfusion 1986, 26 478-480.
41. Weinstein M, Ware JA, Troll J, Salzman E. Changes in von Willebrand factor during cardiac surgery Effect of desmopressin acetate Blood 1988,71. 1.648-1 655
42. Rifón J, Páramo JA, Prosper F, Collados MT, Sarrá J, Rocha E. Thrombin-antithrombin complexes and prothrombin fragment F1 + 2 in aortocoronary bypass surgery: relation to graft occlusion Hemat Pathol 1994, 8. 35-42.
43. Páramo JA, Rifón J, Rocha E Alteraciones de la hemostasia en cirugía extracorpórea: patogénesis y tratamiento Sangre 1993,38: 225-231
44. Addonizio VP, Smith JB, Straus JF, Colman RW, Edmunds LH Jr. Thromboxane synthesis and platelet secretion during cardiopulmonary bypass with bubble oxigenator J Thorac Cardiovasc Surg 1980, 70. 91-96
45. Edmunds LH, Ellison N, Colman RW. Niewiarowski S, Rao AK, Addonizio VP et al Platelet function during cardiac operation. Comparison of membrane and buble oxigenators. J Thorac Cardiovasc Surg 1982; 83. 805-812
46. Fontcuberta J. Gómez JA, Félez J, Borrell M, Brunet S, Rutilant ML. Al-teraciones biológicas de la hemostasia y su correlación con las complicaciones hemorrágicas en la circulación extracorpórea Biol Clin Hematol 1980, 2 245-256
47. Páramo JA, Rifón J, Llorens R, Casares J, Paloma MJ, Rocha E Intra and postoperative fibrinolysis in patients undergoing cardiopulmonary bypass surgery. Haemostasis 1991; 21: 58-64
48. Stibbe J, Kluft C, Brommer EJ Enhanced fibrinolytic activity during cardiopulmonary bypass in open heart surgery in man is caused by extrinsic (tissue type) plasminogen activator. Eur J Clin Invest 1984; 14 375-382.
49. Rifón J, Fernández J, Páramo JA, Cuesta B, Rocha E. Fibrinogen and fibrin degradation products in patients undergoing open-heart surgery. Blood Coag Fibrinol 1990; 1: 509-512.
50. Gram J, Janetzko T, Jepersern J, Bruh HD Enhanced effective fibrinolysis following the neutralization of heparin in open heart surgery increases the risk of postsurgical bleeding Thromb Hemostas 1990, 63: 241-245
51. Rhodes GR, Silver D. Periepicardial fibrinolytic activity: Relation to cardiac bleeding. Surgery 1975, 78; 230-237.
52. Bick RL Hemostasis defects associated with cardiac surgery, prosthetic devices and other extracorporeal circuits Semin Thromb Hemost 1985; 11 249-280
53. Ratnoff OD Some therapeutic agents influencing hemostasis. En. Colma n RW, Hirsh J, Marder VJ, Salzman EW, editores. Hemostasis and thrombosis. Fitadelfia: JB Lippincott Company, 1994, 1.104-1.133
54. Jobes DR, Schwartz AJ. Ellison N. Heparin rebound. J Thorac Cardiovasc Surg 1981, 82: 940-941.
55. Goldman S, Copeland J, Morits T, Henderson W, Zadina K, Ovitt T et al Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy; Results of a Veterans Administration Cooperative Study Circulation 1988; 77; 1.324-1.332
56. Tice DA, Worth MH, Clauss RH, Reed GH. The inhibition by Trasylol of fibrinolytic activity associated with cardiovascular operations. Surg Gynaecol Obst 1964; 119 71-74.
57. Mammen EF. Natural protease inhibitors in extracorporeal circulation Ann NY Acad Sci 1968, 146. 754-762
58. Hack G, Kirchoff PG, Popov-Cenic S, Kulzer R, Schelemminger B. Piepho A Aprotinin bei Operationen am offen Herzen. Med Welt 1983; 34. 726-731
59. Koestering H, Kirchoff PG. Voelker P, Warmann E, Koncz J. Untersuchungen der Blutgerinnungsveraender-ungen wahrend und nach Operationen mit Hilfe der Herz-Lungen-Maschine Thoraxchirurge 1973; 21. 534-543.
60. Huth C, Hoffmeister HE. Einsatz von Proteinasen-inhibitoren waehrend der extrakorporalen Zirkulation-Wirkungsverbesserung durch Optimierung der Dosis m einer kilinischen Studie En: Dudziak R, Kirchhoff PG, Reuter HD Schumann F, editores Proteolyse und Proteinses inhibition m der Herz-und Gefasschirurgie Stuttgart: Schattauer, 1985; 243-253
61. Hannekum A, Reuter HD, Dalichau H, Horpacsy C, Selbherr J. Anlage und zussammenfassendes Ergebnis einer Klinischen Doppelblindstudie bei Operationen am offenen Herzen. Einfluss von Aprotinin auf Thrombozytenzahl und-funktion En. Dudziak R, Kirchhoff PG, Reuter HD, Schumann F, editores Proteolyse und Proteinasen-inhibition in der Herz-und Gefasschirurgie. Stuttgart: Schattauer, 1985; 222-223
62. Popov-Cenic S, Murday H, Kirchhoff PG, Hack G, Fenyes J. Anlage und zusammenfassendes Ergebnis einer klinischen Doppelblindstudie bei aortokoronaren Bypass-Operationen. En Dudziak R, Kirchhoff PG, Reuter HD, Schumann F, editores Proteolyse und Proteinasen-inhibition in der Herz-und Gefasschirurgie. Stuttgart. Schattauer, 1985; 171-186.
63. Royston D, Taylor KM, Bidstrup BP, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987, 5 1.289-1.291.
64. Royston D, Fleming JS, Desai JB, Westaby S, Taylor KM Increased production of peroxidation products associated with cardiac operations. J Thorac Cardiovasc Surg 1986, 91: 756-759.
65. Fraedrich G, Weber C, Bernard C, Hettwer A.Schlosser V. Reduction of blood transfusion requirement in open heart surgery by administration on high doses of aprotinin preliminary results J Thorac Cardiovasc Surg 1989; 37: 89-91.
66. Alajmo F, Calamai G, Perna AM, Melissano G, Petelli P, Palmarini MF et al High dose aprotinin: hemostatic effects in open heart operations. Ann Thorac Surg 1989; 48. 536-539.
67. Dietrich W, Barankay A, Dilthey G, Niekau E, Sebening F, Richter JA Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application clinical experience in 152 cardiac surgical patients. J Thorac Cardiovasc Surg 1989; 37: 92-98.
68. Bidstrup BP, Royston D, Sapsford RN, Taylor KM Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol) J Thorac Cardiovasc Surg 1989; 97; 364-372.
69. Royston D, Bidstrup BP Taylor KM, Sapsford RN. Aprotinin (Trasylol) reduces bleeding after open heart surgery in patients taking aspirin and those with renal failure [resumen] Anesthesiology 1989, 71: 6
70. Harder MP, Eijsman L, Roozendaal KJ, Van Oeveren W, Vildevuur CR Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass Ann Thorac Surg 1991, 51 936-941.
71. Carrel T, Bauer E, Garcia E, Von-Segesser L, Niederhauser U, Schonbeck M et al Reduction of postoperative blood loss and donor blood use in heart surgery with aprotinin, experience with various dosages. Helvet Chir Acta 1991; 58:365-378.
72. Havel M. Teufelsbauer H, Knohl P, Dalmatiner R, Jaksch P, Zweelfer W et al. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc 1991,101:968-972
73. Bidstrup BP. High-dose Aprotinin reduces bleeding in patients taking Aspirin at the time of aorto-coronary bypass surgery. En: Friedel N. Hetzer D, Royston D, editores. Blood use in Cardiac Surgery Nueva York. Springer-Verlag, 1991, 240-244.
74. Cosgrove D, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LA et al. Aprotinin therapy for reoperative myocardial revascularization. a placebo-controlled study Ann Thorac Surg 1992, 54 1.036-1.038.
75. Biagnimi A, Comite C, Russo V, Salerno ML, Gemignani R, Pardelli S et al. High dose aprotinin to reduce blood loss in patients undergoing open heart surgery. Acta Anaesthesiol Bel 1992; 43: 181-186.
76. Dietrich W, Barankay A, Hahbek C, Richter JA. High-dose aprotinin in cardiac surgery. Three years' experience in 1,784 patients J Cardiothorac Vasc Anesth 1992; 6: 324-327
77. Mohr R, Goor DA, Lusky A, Lavee J. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction Circulation 1992; 86 (Supl 2): 405-409.
78. Lawee J, Savion N, Smolinksky A. Goor DA, Mohr R. Platelet protection by aprotinin in cardiopulmonary bypass- electron microscopic study. Ann Thorac Surg 1992; 53: 477-481
79. Huang H, Ding W, Su Z, Zhabg W. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg 1993; 106: 11-18.
80. Matzdorff AC, Green D, Cohen I, Bauer KD Effect of recombinant aprotinin on platelet activation in patients undergoing open heart surgery. Haemostasis 1993; 23: 293-300
81. Ochard MA, Goodchild CS, Prentice CRM, Davies JA, Benoit SE, Creighton-Kemsford LJ et al. Aprotinin reduces cardiopulmonary bypass-induced blood toss and inhibits fibrinolysis without influencing platelets. BrJ Haematol 1993; 85. 533-541.
82. Zuazu I. Estudio clínico-biológico sobre la eficacia de la desmopresina y aprotinina en cirugía extracorpórea. Estudio randomizado a doble ciego [tesis doctoral]. Barcelona Universidad Autónoma de Barcelona, 1994.
83. Rocha E, Hidalgo F, Llorens R, Melero JM, Arroyo JL, Páramo JA. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery Circulation 1994; 90: 921-927
84. Van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CRH. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass J Thorac Cardiovasc Surg 1990, 99. 788-797.
85. Havel M, Owen AN, Simon P, Teufelsbauer H, Zwoelfer W, Laczkovics A et al. Decreasing use of donated blood and reduction of bleeding after orthotopic heart transplantation by use of aprotinin J Heart Lung Transplant 1992; 11: 348-349.
86. Lavee J, Raviv Z, Smolinsky A, Savion N, Varon D, Goor DA et al. Platelet protection by low-dose aprotinin in cardiopulmonary bypass: electron microscopic study. Ann Thorac Surg 1993; 55: 114-119.
87. Royston D. The serine antiprotease aprotinin (Trasylo™): a novel approach to reducing postoperative bleeding Blood Coag Fibrinol 1990, 1: 55-69.
88. Hardy JF, Desroches J, Belisle S, Perrault J, Carrier M, Robitaille D. Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients. Can J Anaesth 1993; 40: 525-631.
89. Tatar H, Cicek S, Demirkilic U, Ozal E, Suer H, Ozturk O, lsiklar H Topical use of aprotinin in open heart operations. Ann Thorac Surg 1993; 55: 659-661.
90. De Bakker A, De Hert S, Vlaemick R, Delrue G, Govaerts E, Vermeyen K. Effects of different forms of aprotinin during cardiopulmonary bypass. Acta Anaesthesiol Belg 1993; 44. 45-51.
91. Royston D. High-dose aprotinin therapy: A review of the first five years' experience. J Cardiovasc Anesth 1991, 6: 76-100.
92. Hardy JF, Desroches J Natural synthetic antifibrinolytic in cardiac surgery. Can J Anaesth 1991; 39: 353-365.
93. Royston D. Clinical effectiveness of aprotinin in heart surgery En Friedel N, Hetzer D, Royston D, editores. Blood use in cardiac surgery Nueva York. Springer-Verlag 1991; 208-220.
94. Bidstrup BP, Royston D, Taylor KM, Sapford RN. Effect of aprotinin on need blood transfusion in patients with septic endocarditis having open heart surgery Lancet 1988, 1: 36-367
95. Bidstrup BP, Ooyston D, McGuiness C, Sapsford RN. Aprotinin reduces bleeding in patients taking aspirin at the time of open heart surgery. Circulation 1989, 80:4 158.
96. Blauhut B. Reply to invited letter concerning: Aprotinin. J Thorac Cardiovasc Surg 1992; 103 386-388.
97. Harker LA Bleeding after cardiopulmonary bypass N Engl J Med 1986; 314 1.446-1.448
98. Kawasuji M, Ueyama K, Sakakibara N, Teodoriya T, Matsunaga Y, Misaki T et al. Effect of low-dose aprotinin on coagulation and fibrmolysis in cardiopulmonary bypass. Ann Thorac Surg 1993, 55: 1 205-1.209.
99. Lu H. Soria C, Commm PL, Soria J, Piwnica A, Schumann F et al. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemostas 1991, 66: 633-637
100. Kim T, Hoppensteadt D, Setal M. The effects of aprotinin treatment during CAGB on TFPI, tissue factor and other hemostatic parameters [resumen] Thromb Haemost 1993; 69: 1.290.
101. Nagaoka H, lnnarni R, Murayama F, Funakoshi N, Hirooka K, Watanabe M et al Effects of aprotinin on prostaglandin metabolism and platelet function in open heart surgery. J Cardiovasc Surg 1991, 32 31-37
102. Miles LSA, Ginsbert MA. White JG, Plow EF. Plasminogen interacts with human platelets through two distinct mechanisms J Clin Invest 1986; 77 2 001-2.009.
103. Lotteberg R, Sjak-Shie N, Fazleabas AT, Roberts RM. Aprotinin inhibits urokinase but not tissue type plasminogen activator. Thromb Res 1989, 49 549-556.
104. Dietrich W, Jochum M, Schramm W, Blumel G, Richter JA. Reduction in homologous blood requirement in cardiac surgery using high dose aprotinin [resumen]. Anesthesiology 1989; 71. 7.
105. Boer H, Flüsher F, Lang J, Vahl C. Early formation of catheters in cardiac surgical patients receiving high-dose aprotinin. J Thorac Cardiovasc Surg 1990; 4. 222-225.
106. Bidstrup BP, Harrison J, Royston D, Taylor KM, Treasure T Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993; 55:971-976.
107. Schulze K, Graeter T, Schaps D, Hausen B Severe anaphylactic shock due to repeated application of aprotinin in patients following intrathoracic aortic replacement. Eur J Cardiothorac Surg 1993; 7: 495-496.
108. Carrera A, Fernéndez P, Garcia del Valle D, De la Quintana B, Martínez MV Propiedades farmacológicas de la aprotinina y empleo terapéutico en cirugía cardíaca. Rev Esp Anestesiol Reanim 1993,40: 292-299
109. Sundt TM, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest Ann Thorac Surg 1993; 55: 1418-1 424.
110. Smet AE, Chang MN, Oeveren W, Roozendal KJ, Wildevuur CR. Increased anticoagulation during cardiopulmonary bypass by aprotinin. J Thorac Cardiovasc Surg 1990, 101. 520-527.
111. Bethune DW. Aprotinin and cardiac surgery [carta]. Br Med J 1991, 303.991.
112. Hunt JB, Segal HC Yacoub MD. Guidelines for monitoring heparin by activated clotting time when aprotinin in used during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1992; 104: 211-212
113. Hunt BJ Aprotinin and cardiac surgery. Br Med J 1991, 303 660-661
114. Páramo JA, Rocha E Hemostasis in advanced liver disease. Semin Thromb Hemost 1993, 19.184-190
115. Mannucci PM, Formen SP. Haemostasis and liver disease En. Colman RW, Hirsh J, Marder VJ, Salzman EW, editores. Hemostasis and Thrombosis. Filadelfia. JP Lippincott, 1982; 595-601.
116. Mannucci PM, Giangrande PLF. Acquired disorders of coagulation. En: Bloom AL, Forbes CD, Thomas AT, Tuddhenham EGD, editores. Haemostasis and thrombosis. Edimburgo: Churchill Livingstone, 1994, 949-968.
117. Fiore L. Levine J, Deykin D. Alterations of hemostasis in patients with liver disease. En. Zakim D, Boyer TD, editores. Hepatoliogy. A textbook of liver disease. Filadelfia: WB Saunders, 1990, 546-571.
118. Rocha E, Marín J, López Borrasca A. Cirrosis hepática y aclaramiento de activadores de la fibrinólisis Rev Clin Esp 1976; 142 144-146.
119. Páramo JA, Fernéndez F, Cuesta B, Rifón J, Pinacho A, Rocha E The role of fibrinolysis in patients with severe chronic liver disease. Biol Clin Hematol 1989; 12, 61-64.
120. Páramo JA, Rifón J, Fernández J, Cuesta B, Rocha E. Thrombin activation and increased fibrinolysis in patients with chronic liver disease. Blood Coag Fibrinol 1991; 2: 227-230.
121. Porte RJ Coagulation and fibrinolysis in orthotopic liver transplantation. current views and insights. Semin Thromb Hemostas 1993, 19: 191-196
122. Sechstein WO. Riess H, Blumhardt G, Himmelreich G, Jochum M, Gerlach H et al. Aprotinin on orthotopic liver transplantation. Semin Thromb Hemost 1993; 19: 262-267.
123. Bontempo FA, Lewis JH, Van Thiel DH, Spero JA, Ragni W, Butler P et al. The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation 1985; 39: 532-536
124. Lewis JH, Bontempo FA, Cornell F, Kiss JE, Larson P, Ragni MV et al. Blood use in liver transplantation. Transfusion 1987, 27 222-225
125. Farrar RP, Hanto DW, Flye MW, Chaplin H Blood component use in orthotopic liver transplantation Transfusion 1988; 28 474-478
126. Chapin JW, Newland MC, Hurlbert BJ Anesthesia for liver transplantation. Semin Liver Dis 1989, 9: 195-201.
127. Porte RJ, Bontempo FA, Knot EAR, Lewis JH, Kant YG, Starzl TE Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 1989, 48. 978-984
128. Harper PL, Luddington RJ, Jennings I. Reardon D, Seaman MJ, Carrell RW et al Coagulation changes following hepatic revascularization during liver transplantation Transplantation 1989, 48. 603-607
129. Himmelreich G, Kierzek B, Neuahus P, Slama KJ, Riess H. Fibrinolytic changes and the influence of the early perfusate in orthotopic liver transplantation with iniraoperative apronnin treatment Transplant Proc 1991; 23: 1 936-1.937.
130. Kang Y. Clinical use of synthetic antifibrinolytic agents during liver transplantation Semm Thromb Hemostas 1993, 19: 258-261
131. Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw BN et al Intraoperative changes in blood coagulation and thromboelastographic monitoring in liver transplantation. Anesth Analg 1985; 97: 1 488-1 501
132. Lewis JH, Bontempo FA, Kang YG Liver transplantation Intraoperative changes in coagulation factors in 100 first transplant Hepatology 1989 9. 710-714.
133. Flute PT, Rake MO, Williams R, Seaman MJ, Calne RY Liver transplantation in man IV Haemorrhage and Thrombosis Br Med J 1969, 3: 20-23.
134. Palareti G, De Rosa V, Fortunato G, Grauso F, Legnani C, Maccaferri M et al. Control of hemostasis during orthotopic liver transplantation. Fibrinolysis 1988; 2 (Supl 3): 61-66.
135. Arnoux D, Boutiére B, Houvenaeghel M, Rousset-Rouvière A, Le Treut P. Sampol J Intraoperative evolution of coagulation parameters and t-PA/PAI balance in orthotopic liver transplantation Thromb Res 1989, 55: 319-328
136. Dzik WH, Arkin CF, Jenkins RL, Strump DC Fibrinolysis during liver transplantation in humans: Role of tissue-type plasminogen activator. Blood 1988, 71.1.090-1.095
137. Owen CA, Rettke SR, Bowie FJW, Cole TL, Jensen CC, Wiesner RH et al. Hemostatic evaluation of patients undergoing liver transplantation. Mayo Clinc Proc 1987; 62: 761-772
138. Homatas J, Wasantapruek S, von Kaulla E, von Kaulla KN, Einsenman B Clotting abnormalities following orthotopic and heterotopic trans-plantation of marginally preserved pig livers. Acta Hepato-Splenol 1969; 2: 14-27
139. Groth CG, Pechet L, Starzl TE Coagulation during and after orthotopic transplantation on the human liver. Arch Surg 1969; 98: 31 34.
140. Porte RJ, Knot EAR, Bontempo FA. Hemostasis in liver transplantation. Gastroenterology 1989, 97: 488-501.
141. Bohmig HJ. The coagulation disorder of orthotopic hepatic transplantation Semin Thromb Hemost 1977; 4. 57-82.
142. Palareti G, Legagni C, Maccaterri M, Gozzetti G, Mazziotti A, Martinelli G et al Coagulation and fibrinolysis in orthotopic liver transplantation. The role of the recipient's disease and the use of antithrombin-lll concentrates. Haemostasis 1991; 21:67-76.
143. Smokovitis A Normal liver actually possesses a high vascular plasminogen activator activity Experientia 1979; 35: 776-777.
144. Neuhaus P, Bechstein WO, Lefebre B, Blumhardt G, Slama K. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver trasplantation Lancet 1989; 2.924-925.
145. Mallet SV, Cox D, Burroughs AK, Rolles K. Aprotinin and reduction of blood loss and transfusion requirements in orthotopic liver transplantation. Lancet 1990; 336: 886-887.
146. Mallet S, Rolles K, Cox D, Burroughs A, Hunt B. Intraoperative use of aprotinin (Trasylol) in orthotopic liver transplantation. Transplant Proc 1991;23.1 931-1.932.
147. Bechstein WO, Riess H, Neuhaus P, Himmelreich G, Steffen R, Slama KJ et al. The effect of aprotinin of blood product requirements during orthotopic liver transplantation. Clin Transplant 1991; 5: 422-426
148. Grosse H, Lobbes W, Frambach M, Von Broen O, Ringe B. Barthels M The use of high dose aprotinin in liver transplantation. The influence of fibrinolysis and blood loss Thromb Res 1991; 63. 287-297
149. Smith O, Hazlehurst G, Brozovic G, Rolles K, Burroughs A, Mallett S et al Impact of aprotinin on blood transfusion requirements in liver transplantation Transfus Med 1993; 3: 97-102
150. Grosse H, Lobbes W, Frambach M, Ringe B, Barthels M. Influence on high-dose aprotinin on hemostasis and blood requirement in orthotopic liver transplantation. Semin Thromb Hemost 1993; 19: 302-305.
151. Groh J, Welte M, Azad SC, Anthuber M, Haller M, Kratzer MAA. Does aprotinin really reduce blood in orthotopic liver transplantation? Semin Thromb Hemost 1993; 19: 306-308.
152. Suárez M, Sangro B, Herrero JI, Picardi A, Páramo JA, Quiroga J et al. Effectiveness of Aprotinin in Orthotopic Liver Transplantation Semin Thromb Hemost 1993; 19: 292-296.
153. Himmelreich G, Muser M, Neuhaus P, Bechstein WD, Slama KJ, Jochum M et al. Different aprotinin applications influencing hemostatic changes in orthotopic liver transplantation. Transplantation 1992; 53: 132-136
154. Welte M, Groh J, Azad S, Anthuber M, Haller M, Kratzer MAA Effect of aprotinin on coagulation parameters in liver transplantation Semin Thromb Hemost 1993; 19: 297-299.
155. Lie TS, Seger R, Hong GS, Preissinger H. Ogawa K Protective effect of aprotinin on ischemic hepatocellular damage Transplantation 1989, 48:396-399.
156. Beck OJ, Oeckler R Subarach haemorrhage [carta]. Br Med J 1982; 284.1 050.
157. Tzonos T, Giromini D. Aprotinin for intraoperative haemostasis Neurosurg Rev 1981, 4: 1934-94.
158. Ketterl R, Hass S, Heiss A, fritsche HM, Lechner F, Kienzle H et al. Zur Wirkung des natürlichen Proteinaseinhibitors Aprotinin auf die Plattchenfunktion beim alloarthropastischen Huftgelenkersatz. Mediszinische Welt 1982, 33: 480-486.
159. Janssens M, Joris J, David JL, Lemaire R, Lamy M. High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Anesthesiology 1994; 80 23-29
160. Thompson JF, Roath OS, Francis JL, Webster JHH, Chant ADB. Aprotinin in peripheral vascular surgery. Lancet 1990; 335:911
161. Kösters S, Wand H Über die Beeinflussung des Blutverlustes nach Prostataoperationen durch pra-öperative Applikation von Antifibrinolytika Urologe 1973; 12: 295-296